Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Katsuhiko Takabayashi, Fumihiko Ando & Takahiro Suzuki. (2019) Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data. Modern Rheumatology 29:1, pages 87-97.
Read now
Read now
Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Koichi Fujii, Takunari Yoshinaga, Bruce Freundlich & Michio Suzukawa. (2011) Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Modern Rheumatology 21:4, pages 343-351.
Read now
Read now
Juan Li, EricM. Chi, Chunyao Feng & Shein-Chung Chow. (2011) Imputation Method Adjusted for Covariates for Nonrespondents in Instruments with Applications. Journal of Biopharmaceutical Statistics 21:2, pages 342-354.
Read now
Read now
Wayne N Burton, Alan Morrison, Yong Yuan, Tracy Li, Riccardo E Marioni & Ross Maclean. (2008) Productivity cost model of the treatment of rheumatoid arthritis with abatacept. Journal of Medical Economics 11:1, pages 3-21.
Read now
Read now
Chenglong Han, Ning Zhao, Abizer Gaslightwala & Mohan Bala. (2007) An epidemiological and healthcare utilisation study of rheumatoid arthritis in an adult population in the US. Journal of Medical Economics 10:4, pages 489-499.
Read now
Read now
Arthur L. Weaver, Richard L. Lautzenheiser, Michael H. Schiff, Allan Gibofsky, James L. Perruquet, John Luetkemeyer, Harold E. Paulus, H. Amy Xia & Jonathan A. Leff. (2006) Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Current Medical Research and Opinion 22:1, pages 185-198.
Read now
Read now
Articles from other publishers (35)
Yinan Huang, Sandeep K. Agarwal, Hua Chen, Satabdi Chatterjee, Michael L. Johnson & Rajender R. Aparasu. (2023) Real-World Comparative Effectiveness of Methotrexate-Based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clinical Therapeutics.
Crossref
Crossref
Nik-Madihah Nik-Azis, Nurulhuda Mohd, Fazalina Mohd Fadzilah, Nor Hazla Mohamed Haflah, Mohd Shahrir Mohamed Said & Badiah Baharin. (2021) Rheumatoid arthritis serotype and synthetic disease-modifying anti-rheumatic drugs in patients with periodontitis: A case-control study. PLOS ONE 16:6, pages e0252859.
Crossref
Crossref
Chi Zhang, Daogang Guan, Miao Jiang, Chao Liang, Li Li, Ning Zhao, Qinglin Zha, Wandong Zhang, Cheng Lu, Ge Zhang, Jian Liu & Aiping Lu. (2019) Efficacy of leflunomide combined with ligustrazine in the treatment of rheumatoid arthritis: prediction with network pharmacology and validation in a clinical trial. Chinese Medicine 14:1.
Crossref
Crossref
Sara Monti, Vittorio Grosso, Monica Todoerti & Roberto Caporali. (2018) Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology 57:Supplement_7, pages vii54-vii58.
Crossref
Crossref
Priyanka Vashisht, Harlan Sayles, Amy C. Cannella, Ted R. Mikuls & Kaleb Michaud. (2016) Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. Arthritis Care & Research 68:10, pages 1478-1488.
Crossref
Crossref
Abdul Samad, Abdul Khalil, Iftikhar Ali & Aziz Ullah Khan. (2016) Methotrexate‐induced pneumonitis in a patient with rheumatoid arthritis: a case report. Journal of Pharmacy Practice and Research 46:3, pages 256-260.
Crossref
Crossref
Matthew Geisz, Christina Ha, Michael D. Kappelman, Christopher F. Martin, Wenli Chen, Kristen Anton, Robert S. Sandler & Millie D. Long. (2016) Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 22:6, pages 1435-1441.
Crossref
Crossref
Lydia Abasolo, Leticia Leon, Luis Rodriguez-Rodriguez, Aurelio Tobias, Zulema Rosales, Jose Maria Leal, Victor Castaño, Cristina Vadillo, Pilar Macarron, Oscar Fontsere & Juan Angel Jover. (2015) Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions. Seminars in Arthritis and Rheumatism 44:5, pages 506-513.
Crossref
Crossref
John Koo, Ethan Levin, Argentina Leon, Jashin Wu & Alice GottliebJason Emer & Mark Lebwohl. 2014. Moderate to Severe Psoriasis, Fourth Edition. Moderate to Severe Psoriasis, Fourth Edition
121
138
.
Joseph A. Markenson, Andrew S. Koenig, Jing Yuan Feng, Sandeep Chaudhari, Debra J. Zack, David Collier & Arthur Weaver. (2013) Comparison of Physician and Patient Global Assessments Over Time in Patients With Rheumatoid Arthritis. Journal of Clinical Rheumatology 19:6, pages 317-323.
Crossref
Crossref
Arthur Weaver, Orrin Troum, Michele Hooper, Andrew S. Koenig, Sandeep Chaudhari, JingYuan Feng & Deborah Wenkert. (2013) Rheumatoid Arthritis Disease Activity and Disability Affect the Risk of Serious Infection Events in RADIUS 1. The Journal of Rheumatology 40:8, pages 1275-1281.
Crossref
Crossref
Federico Augustovski, Andrea Beratarrechea, Vilma Irazola, Fernando Rubinstein, Pablo Tesolin, Juan Gonzalez, Verónica Lencina, Marina Scolnik, Christian Waimann, David Navarta, Gustavo Citera & Enrique R. Soriano. (2013) Patient Preferences for Biologic Agents in Rheumatoid Arthritis: A Discrete-Choice Experiment. Value in Health 16:2, pages 385-393.
Crossref
Crossref
J. Zeidler, H. Zeidler & J.-M. Graf von der Schulenburg. (2012) Therapie der rheumatoiden Arthritis mit MethotrexatTherapy of rheumatoid arthritis with methotrexate. Zeitschrift für Rheumatologie 71:10, pages 900-907.
Crossref
Crossref
Arun Shrivastava & Dhanita Khanna. (2012) CHOPping the biologics?!. Indian Journal of Rheumatology 7:1, pages 29-34.
Crossref
Crossref
Daniel H. Solomon, John Z. Ayanian, Ed Yelin, Tamara Shaykevich, M. Alan Brookhart & Jeffrey N. Katz. (2012) Use of disease‐modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. Arthritis Care & Research 64:2, pages 184-189.
Crossref
Crossref
John J. Cush. 2012. Great Health Care. Great Health Care
123
136
.
Sarika Ogale, Elena Hitraya & Henry J Henk. (2011) Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskeletal Disorders 12:1.
Crossref
Crossref
Alexandra N Colebatch, Jonathan L Marks & Christopher J Edwards. (2011) Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database of Systematic Reviews.
Crossref
Crossref
JOSEPH A. MARKENSON, ALLAN GIBOFSKY, WILLIAM R. PALMER, EDWARD C. KEYSTONE, MICHAEL H. SCHIFF, JINGYUAN FENG & SCOTT W. BAUMGARTNER. (2011) Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry. The Journal of Rheumatology 38:7, pages 1273-1281.
Crossref
Crossref
Michael A. Lane, Jay R. McDonald, Angelique L. Zeringue, Liron Caplan, Jeffrey R. Curtis, Prabha Ranganathan & Seth A. Eisen. (2011) TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis. Medicine 90:2, pages 139-145.
Crossref
Crossref
Ronald F. van Vollenhoven & Johan L. Severens. (2010) Observational studies: a valuable source for data on the true value of RA therapies. Clinical Rheumatology 30:S1, pages 19-24.
Crossref
Crossref
ALLAN GIBOFSKY, WILLIAM R. PALMER, EDWARD C. KEYSTONE, MICHAEL H. SCHIFF, JINGYUAN FENG, PETER McCROSKERY, SCOTT W. BAUMGARTNER & JOSEPH A. MARKENSON. (2011) Rheumatoid Arthritis Disease-modifying Antirheumatic Drug Intervention and Utilization Study: Safety and Etanercept Utilization Analyses from the RADIUS 1 and RADIUS 2 Registries. The Journal of Rheumatology 38:1, pages 21-28.
Crossref
Crossref
Jean-Marie Berthelot, Stéphanie Benoist-Gérard, Benoît le Goff, Florence Muller-Chevalet & Yves Maugars. (2010) Outcome and safety of TNFα antagonist therapy in 475 consecutive outpatients (with rheumatoid arthritis or spondyloarthropathies) treated by a single physician according to their eligibility for clinical trials. Joint Bone Spine 77:6, pages 564-569.
Crossref
Crossref
Milka Maravic. (2010) Impact économique des biothérapies dans le traitement de la polyarthrite rhumatoïde (PR) en France. Revue du Rhumatisme 77:5, pages 474-479.
Crossref
Crossref
P Taylor, B Manger, J Alvaro-Gracia, R Johnstone, J Gomez-Reino, E Eberhardt, F Wolfe, S Schwartzman, N Furfaro & A Kavanaugh. (2010) Patient Perceptions concerning Pain Management in the Treatment of Rheumatoid Arthritis. Journal of International Medical Research 38:4, pages 1213-1224.
Crossref
Crossref
Jean-Marie Berthelot, Stéphanie Benoist-Gérard, Benoît le Goff, Florence Muller-Chevalet & Yves Maugars. (2010) Réponse et tolérance aux anti-TNF des 475 premiers patients (polyarthrites rhumatoïdes ou spondylarthrites) traités par un même praticien, selon la capacité de ceux-ci à participer ou non aux études pivots. Revue du Rhumatisme 77:4, pages 344-349.
Crossref
Crossref
Milka Maravic. (2010) Economic impact of rheumatoid arthritis (RA) biotherapies in France. Joint Bone Spine 77:4, pages 319-324.
Crossref
Crossref
Leona Cuttler, Detelina Marinova, Mary Beth Mercer, Alfred Connors, Rebecca Meehan & J B. Silvers. (2009) Patient, Physician, and Consumer Drivers. Medical Care 47:8, pages 858-865.
Crossref
Crossref
Charles J. Malemud. (2009) The Discovery of Novel Experimental Therapies for Inflammatory Arthritis. Mediators of Inflammation 2009, pages 1-16.
Crossref
Crossref
Jason Emer. 2008. Moderate-to-Severe Psoriasis, Third Edition. Moderate-to-Severe Psoriasis, Third Edition
193
217
.
B. Chikura, N. Sathi, S. Lane & J. K. Dawson. (2008) Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology 47:11, pages 1647-1650.
Crossref
Crossref
Kenneth G. Saag, Gim Gee Teng, Nivedita M. Patkar, Jeremy Anuntiyo, Catherine Finney, Jeffrey R. Curtis, Harold E. Paulus, Amy Mudano, Maria Pisu, Mary Elkins‐Melton, Ryan Outman, Jeroan J. Allison, Maria Suarez Almazor, S. Louis BridgesJr.Jr., W. Winn Chatham, Marc Hochberg, Catherine Maclean, Ted Mikuls, Larry W. Moreland, James O'dell, Anthony M. Turkiewicz & Daniel E. Furst. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care & Research 59:6, pages 762-784.
Crossref
Crossref
Pradip Nandi, Gabrielle H Kingsley & David L Scott. (2008) Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis. Current Opinion in Rheumatology 20:3, pages 251-256.
Crossref
Crossref
Edward C Keystone. (2006) Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists—an opportunity to improve outcomes. Nature Clinical Practice Rheumatology 2:11, pages 594-601.
Crossref
Crossref
Alexander Kai-Lik So & Jonathan Kay. (2006) Preface. Best Practice & Research Clinical Rheumatology 20:4, pages 623-625.
Crossref
Crossref